[ad_1]
The Center for Molecular Immunology of Cuba (CIM) highlighted this Wednesday that the drug Itolizumab, developed in collaboration with an Indian company, has received authorization to begin a phase III clinical trial on patients with Covid-19 in the United States ( USA). .), Mexico and Brazil.
READ ALSO:
Cuban vaccine candidate Soberana 02 enters the WHO list
Together with the company India Biocon, this trial will consolidate the scientific evidence that supports the effective inclusion of the drug in the Cuban protocol for the treatment of the disease, warns the CIM through its Twitter account.
The experts ensured that this innovative product of Cuban biotechnology has made it possible to reduce the number of patients with evolution at critical stages. The drug also has an anti-inflammatory and immunoregulatory effect.
The Itolizumab monoclonal antibody developed by our company in collaboration with the Indian company #Biocon, receives authorization to start a phase III clinical trial on patients with # COVID19 in the United States, Mexico and Brazil. pic.twitter.com/G36GDESkbw
– Center for Molecular Immunology (CIM) (@centro_cim)
November 4, 2020
Recently, Cuban researchers also shared on social networks an article published in the journal Gerontology on the experience on the island of the use of Itolizumab in elderly patients with Covid-19.
According to the text, the study combined the timely use of this monoclonal antibody with other antiviral and anticoagulant therapies to reduce disease worsening and mortality.
The text also mentioned that the humanized antibody Itolizumab emerges as a therapeutic alternative for patients with Covid-19. Among the beneficiaries of this treatment stand the elderly with multiple comorbidities, susceptible to adverse clinical outcomes in the course of viral infection.
According to specialists, this treatment is significantly associated with a decrease in the risk of hospitalization in the intensive care unit and a 10-fold reduction in the risk of death.
[ad_2]
Source link
